Bio-Techne Corporation Earnings Recaps
Q3 2026
May 7, 2026
Bio-Techne’s shares fell 10.2% following the quarter, as investor disappointment centered on continued organic revenue deceleration driven by emerging biotech weakness and cautious near-term outlook despite some pockets of growth and margin improvement.
Key takeaways
- Organic revenue declined 2% for the quarter, weighed down by high single-digit declines in emerging biotech spending.
- Large pharma segment sustained low double-digit growth for its sixth consecutive quarter, while U.S. academia returned to low single-digit growth.
- Adjusted operating margin improved sequentially by 310 basis points to 34.2%, reflecting disciplined cost management.
- Order timing from two fast track cell therapy customers and a large OEM supply order created a 400 basis point headwind.
- China market continued positive organic growth for the fourth quarter in a row, driven by demand in biopharma and CRO sectors.
Q2 2026
Feb 4, 2026
Bio-Techne's Q2 FY2026 results showed flat organic revenue growth due to external market pressures, though large pharma demand remained strong and profitability improved, reflecting solid operational execution.
Key takeaways
- Organic revenue growth was flat, impacted by timing effects from FDA Fast Track designations for key cell therapy customers.
- Adjusted operating margins expanded by 100 basis points year-over-year to 31.1%, demonstrating a focus on productivity and cost management.
- Large pharma revenue grew in low double digits, while emerging biotech customers faced mid-single-digit declines amid challenging funding conditions.
- Significant growth in spatial biology bookings and a strong performance across Asia, particularly China, highlight emerging opportunities.
- Core growth verticals now account for 47% of total revenue, with an upper teens CAGR over the past five years, driving future potential.